MAD2 (S-20): sc-31788



The Power to Question

BACKGROUND

Cell cycle progression is subject to arrest at the mitotic spindle assembly checkpoint in response to incorrect spindle fiber assembly. MAD2 (for mitotic arrest-deficient) is a component of the mitotic spindle checkpoint. Cells with mutated MAD2 do not undergo mitotic arrest in response to incorrect spindle fiber assembly, which results in missegregation and eventual cell death. A breast carcinoma cell line with reduced MAD2 expression, T47D, was shown to complete mitosis in the presence of nocodazole, an inhibitor of mitotic spindle assembly. MAD2 is localized to unattached kinetochores during prometaphase and disassociates upon spindle fiber attachment, indicating that MAD2 regulates kinetochore binding to the spindle fibers. Human MAD2 has also been shown to associate with Insulin receptor (IR), but not IGFIR, implicating MAD2 as a mediator for IR-specific signaling. MAD2B, a MAD2 homolog, is required for the execution of the mitotic checkpoint monitoring the kinetochore-spindle attachment process and if the process is not complete, MAD2B delays the onset of anaphase.

CHROMOSOMAL LOCATION

Genetic locus: MAD2L1 (human) mapping to 4q27; Mad2l1 (mouse) mapping to 6 C1.

SOURCE

MAD2 (S-20) is an affinity purified goat polyclonal antibody raised against a peptide mapping within an internal region of MAD2 of human origin.

PRODUCT

Each vial contains 200 μg lgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-31788 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

MAD2 (S-20) is recommended for detection of MAD2 of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 μ g per 100-500 μ g of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

MAD2 (S-20) is also recommended for detection of MAD2 in additional species, including equine, canine, bovine, porcine and avian.

Suitable for use as control antibody for MAD2 siRNA (h): sc-35837, MAD2 siRNA (m): sc-35838, MAD2 shRNA Plasmid (h): sc-35837-SH, MAD2 shRNA Plasmid (m): sc-35838-SH, MAD2 shRNA (h) Lentiviral Particles: sc-35837-V and MAD2 shRNA (m) Lentiviral Particles: sc-35838-V.


Molecular Weight of MAD2: 25 kDa.

Positive Controls: K-562 nuclear extract: sc-2130, Jurkat nuclear extract: sc-2132 or MAD2 (h): 293T Lysate: sc-177506.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunoprecipitation: use Protein A/G PLUS-Agarose: sc-2003 (0.5 ml agarose/2.0 ml). 3) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

DATA



HAD2 (5-28) vs. 21732. We stern his boosty is of HAD2 expression in one draw factor: vs. 11772. (A) and harms HAD2 traw factor: vs. 17735. (\$) 207 Chair cell feedby.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.



Try MAD2 (C-10): sc-374131 or MAD2 (17D10): sc-47747, our highly recommended monoclonal alternatives to MAD2 (S-20).

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3801 Fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com